A Three-Way Crossover Study to Evaluate the ECG Effects of Telaglenastat in Healthy Adult Subjects
Latest Information Update: 12 Mar 2021
At a glance
- Drugs Telaglenastat (Primary) ; Moxifloxacin
- Indications Breast cancer; Cancer; Colorectal cancer; Leukaemia; Malignant melanoma; Multiple myeloma; Myelodysplastic syndromes; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions
- Sponsors Calithera Biosciences
- 08 Mar 2021 Status changed from recruiting to completed.
- 30 Oct 2020 New trial record